Yi Liu

A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways

This paper develops a niclosamide sulfate prodrug, SSL-0024, which improves solubility and bioavailability, showing strong anti-tumor effects against hepatocellular carcinoma through multiple pathway inhibition.

Niclosamide Prodrug Enhances Oral Bioavailability and Targets Vasorin-TGFβ Signaling in Hepatocellular Carcinoma

This study develops a niclosamide prodrug (NIC-PS) with improved bioavailability and shows it targets VASN-TGFβ signaling to reduce HCC tumor volume and enhance therapeutic responses.